Quick Answer
CARLSMED, INC. reported Net Income of -$29.63 million for fiscal year 2025.
CARLSMED, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$29.63M -22.2% |
-$24.26M | — |
| Diluted EPS | -$2.12 +65.3% |
-$6.11 | — |
| Total Assets | $130.12M +151.1% |
$51.82M | — |
| Cash and Equivalents | $85.79M +113.8% |
$40.12M +455.6% |
$7.22M |
| Long-Term Debt | $15.35M -0.4% |
$15.41M | — |
| Stockholders Equity | $98.87M +240.0% |
-$70.63M -53.1% |
-$46.13M |
| R&D Expense | $17.02M +19.0% |
$14.30M | — |
| Operating Income | -$30.57M -26.7% |
-$24.12M | — |
| Gross Profit | $38.04M +89.7% |
$20.05M | — |
| Shares Outstanding | 26.60M +542.7% |
4.14M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.53M | -9.1% | -26.0% |
| Diluted EPS | September 30, 2025 | -$0.40 | +80.6% | +72.8% |
| Total Assets | September 30, 2025 | $134.86M | — | +153.2% |
| Cash and Equivalents | September 30, 2025 | $115.37M | +159.6% | +244.7% |
| Long-Term Debt | September 30, 2025 | $15.44M | — | +0.1% |
| Stockholders Equity | September 30, 2025 | $106.66M | +261.5% | +228.4% |
| R&D Expense | September 30, 2025 | $4.45M | +10.2% | +6.9% |
| Operating Income | September 30, 2025 | -$9.04M | -16.2% | -39.0% |
| Gross Profit | September 30, 2025 | $9.93M | +106.9% | +11.9% |
| Shares Outstanding | September 30, 2025 | 26.58M | — | +477.4% |
- CARLSMED, INC. reported Net Income of -$29.63 million for fiscal year 2025.
- CARLSMED, INC. showed a decrease of -22.2% in Net Income compared to the prior fiscal year.
- CARLSMED, INC. reported Diluted EPS of $2.12 per share (loss) for fiscal year 2025.
- CARLSMED, INC. showed an increase of +65.3% in Diluted EPS compared to the prior fiscal year.
- CARLSMED, INC. reported Total Assets of $130.12 million for fiscal year 2025.
- CARLSMED, INC. showed an increase of +151.1% in Total Assets compared to the prior fiscal year.
- CARLSMED, INC. reported Cash and Equivalents of $85.79 million for fiscal year 2025.
- CARLSMED, INC. showed an increase of +113.8% in Cash and Equivalents compared to the prior fiscal year.
- CARLSMED, INC. reported Long-Term Debt of $15.35 million for fiscal year 2025.
- CARLSMED, INC. showed a decrease of -0.4% in Long-Term Debt compared to the prior fiscal year.
- CARLSMED, INC. reported Stockholders Equity of $98.87 million for fiscal year 2025.
- CARLSMED, INC. showed an increase of +240.0% in Stockholders Equity compared to the prior fiscal year.
- CARLSMED, INC. reported R&D Expense of $17.02 million for fiscal year 2025.
- CARLSMED, INC. showed an increase of +19.0% in R&D Expense compared to the prior fiscal year.
- CARLSMED, INC. reported Operating Income of -$30.57 million for fiscal year 2025.
- CARLSMED, INC. showed a decrease of -26.7% in Operating Income compared to the prior fiscal year.
- CARLSMED, INC. reported Gross Profit of $38.04 million for fiscal year 2025.
- CARLSMED, INC. showed an increase of +89.7% in Gross Profit compared to the prior fiscal year.
- CARLSMED, INC. reported Shares Outstanding of 26.60 million shares for fiscal year 2025.
- CARLSMED, INC. showed an increase of +542.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: